scispace - formally typeset
P

P.R. Schuurman

Researcher at University of Amsterdam

Publications -  44
Citations -  3059

P.R. Schuurman is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Deep brain stimulation & Medicine. The author has an hindex of 21, co-authored 31 publications receiving 2840 citations.

Papers
More filters
Journal ArticleDOI

A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor

TL;DR: In this paper, the effects of these two procedures on the functional abilities of patients with drug-resistant tremor due to Parkinson's disease, essential tremor, or multiple sclerosis were examined.
Journal ArticleDOI

Neuropsychological effects of bilateral STN stimulation in Parkinson disease: A controlled study

TL;DR: In this article, the authors evaluated the cognitive and behavioral effects of bilateral subthalamic nucleus (STN) stimulation in patients with Parkinson disease (PD) 6 months after surgery and found that the STN group showed a larger decline than the control group on measures of verbal fluency, color naming, selective attention, and verbal memory.
Journal ArticleDOI

Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: a randomized trial.

TL;DR: In this article, the authors compared the efficacy of unilateral pallidotomy and bilateral subthalamic nucleus (STN) stimulation in patients with advanced Parkinson disease (PD) in a randomized, observer-blind, multicenter trial.
Journal ArticleDOI

Pathological gambling after bilateral subthalamic nucleus stimulation in Parkinson disease

TL;DR: A patient with advanced Parkinson’s disease who developed pathological gambling within a month after successful bilateral subthalamic nucleus (STN) stimulation appears to be related to a combination of bilateral STN stimulation and treatment with dopamine agonists.
Journal ArticleDOI

Deep brain stimulation in addiction: a review of potential brain targets

TL;DR: The analysis of the literature suggests that the NAc is currently the most promising DBS target area for patients with treatment-refractory addiction, and the mPFC is another promising target, but needs further exploration to establish its suitability for clinical purposes.